Skip to main content
Premium Trial:

Request an Annual Quote

Applied Biosystems Obtains License for ICAT Reagents

NEW YORK, Nov 17 – Applied Biosystems said Friday it has obtained the exclusive license from the University of Washington to manufacture and commercialize the isotope coded affinity tagging reagents.

Applied Biosystems expects to start selling its first ICAT product in the first half of next year. Terms of the deal were not disclosed.

Ruedi Aebersold of the Institute for Systems Biology in Seattle developed the ICAT technology while he was a professor at the University of Washington. The ICAT reagents are designed to facilitate separating and tagging proteins found in tissues that researchers wish to compare.

Once the proteins are marked by the ICAT reagents they can then be analyzed by a mass spectrometer, giving researchers the opportunity to better understand how diseases behave at the molecular level.

“This technology is intended to bring added benefits in terms of identifying and quantifying important low abundance and membrane proteins,” Joseph Malandrakis, general manager of the PerSeptive Biosystems business unit of Applied Biosystems, said in a statement.

“The ICAT reagent chemistry is a platform technology that we expect to embody in a family of reagents and instrument systems over time,” he said.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.